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The concept of using antibodies as ‘magic bullets’ for cancer
therapy has shown a remarkable revival. Recently highly encour-
aging results have been reported with antibodies targeting EGP-
2/EpCAM on carcinomas (Edrecolomab; Riethmuller et al, 1998),
HER-2/neu on breast cancers (Trastuzumab; Cragg et al, 1999)
and CD20 on lymphomas (Rituximab; Rosen, 1999). Impressive
response rates are obtained with these antibodies alone or in
combination with additional chemo-therapeutic and/or radio-
therapeutic regimens, without showing significant cytotoxicity. 
The most promising of these antibodies are those targeting the
B-cell differentiation marker CD20. These antibodies have been
used for treatment of non-Hodgkin lymphoma (NHL) patients, as
more than 90% of all non-Hodgkin lymphomas are positive for
CD20. After Rituximab-treatment 50% of patients with advanced,
indolent NHL showed partial or complete responses (Rosen,
1999). Because CD20 is expressed on B-cells during a number of
stages of B-cell development, but is absent from B-cell progenitor
cells and mature plasma cells (Rudin and Thompson, 1998), anti-
CD20-antibodies do compromise the patient’s immune system
only to a limited extent. 
The effectivity of Rituximab can probably be explained by its
supposed dual effector function. First it is known that antibodies
retarget the immune system to antibody-coated cells via their Fc-
tail, leading ultimately to death of the cell by complement me-
diated lysis and/or antibody-dependent cellular cytotoxicity.
Secondly, it has been shown that binding of antibodies to CD20
can modulate B-cell proliferation and/or antibody-dependent
cellular cytotoxicity and that cross-linking of anti-CD20-
antibodies (e.g. by Fc-receptor positive cells) on B-cells can
lead to apoptosis of the target cell (Shan et al, 1998, 2000). The
latter effects are thought to contribute significantly to the effi-
ciency of treatment with this ‘signalling antibody’ (Cragg et al,
1999). 
Although the results obtained with Rituximab are very
promising it is important to note that anti-CD20-treatment is not
curative and that treated patients may relapse ultimately. In order
to improve upon the efficiency of anti-CD20-antibody treatment
several strategies have been investigated. One approach is the
labelling of the antibodies with radioisotopes to induce local irra-
diation. In another approach toxins are coupled to the antibodies
and by this means delivered to tumour cells. Also combination
therapy regimens consisting of Rituximab and chemotherapy have
been tested in clinical trials (Rosen, 1999). Although these
approaches are indeed more successful (higher response rates were
achieved) increased toxicity to normal tissues may be expected. 
We have focused in the past on the development of bispecific
antibodies which are designed to retarget T-cells to tumour (asso-
ciated) antigens. In the setting of NHL it might be expected that bi-
specific antibody-mediated retargeting of T-cells to CD20-positive
tumour cells will induce apoptosis more efficiently than CD20-
cross-linking alone, because T-cells are equipped to optimally
induce apoptosis in target cells. 
In this paper we describe the production and characteriza-
tion of the bi-specific antibody BIS20x3 via hybrid hybridoma
techniques. BIS20x3 recognizes CD20 with one chain and CD3e
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was observed after application of BIS20x3 and subsequent indirect
cross-linking via CD20-positive cells. The results presented in this
paper demonstrate that BIS20x3 is an attractive candidate for
being tested as a new treatment modality for CD20-positive malig-
nancies. B-cell malignancies may be ideal targets for T-cell
retargeting bi-specific antibodies because B-cells may efficiently
co-stimulate the effector T-cells. 
MATERIALS AND METHODS 
Culture media and other reagents 
RPMI 1640 medium (containing 25 mM Hepes and L-glutamin)
and 100x HT-supplement were obtained from Bio-Whittaker
(Verviers, Belgium) and FCS from Bodinco BV (Alkmaar, The
Netherlands). Culturing ‘additives’ consist of 1 mM sodium 
pyruvate (Bio-Whittaker), 2 mM L-glutamin (Bio-Whittaker),
0.5 mM b-mercaptoethanol, 0.1 mg ml–1 gentamycin sulphate 
(Bio-Whittaker), and fungizone (Amfotericine-B, Bristol-Myers
Squibb, Woerden, The Netherlands). Hygromycin was purchased
from Roche Molecular Biochemicals (Almere, The Netherlands),
PFHM-II (protein-free hybridoma medium) containing glutamax-I
from Gibco BRL-Life Technologies (Breda, The Netherlands),
calcein-AM from Molecular Probes (Leiden, The 
Netherlands), protein-A (PROSEP®-A) from Bioprocessing Ltd
(ImmunoSource, Zoersel-Halle, Belgium), and Triton X-100,
propidium iodide (PI) and RNase-A from Sigma-Aldrich Chemie
BV (Zwijndrecht, The Netherlands). Lymfoprep was obtained
from Nycomed Pharma AS (Oslo, Norway) and serum- and
phenolred-free medium (X-VIVOTM) from Bio-Whittaker. 
Hybridomas, quadroma and cell lines 
Hybridoma and quadroma cell lines were cultured in RPMI 1640
medium containing 15% FCS, 15% ESG (conditioned ES-1-
culture medium, IQ-Products, Groningen, The Netherlands),
additives (see above), and HT-supplement. All other cell lines
were cultured in essentially the same medium, however without
conditioned ES-1 culture medium and HT supplement. All cells
were cultured at 37˚C, in a humidified atmosphere containing 5%
CO2. The EBV-immortalized human B-cell line JY was obtained
from Dr L Bakker (Dept. Tumor Immunology, Nijmegen, the
Netherlands). CTLL/CD3e is a mouse T-cell line transfected with
cDNA encoding human CD3e (Helfrich et al, 1998). Jurkat-AM,
which was obtained from Dr P Schrier (University Hospital
Leiden, Leiden, The Netherlands), was cultured in the presence of
0.5 mg ml–1 hygromycin in order to select for NFAT-luc (the
reporter gene luciferase under control of the NFAT-promoter)
positive cells. 
Commercial antibodies 
FITC-, TRITC- or PE-labelled anti-lgG1- or anti-lgG2b-antibodies
were obtained from Becton Dickinson (Erembodegem-Aalst,
Belgium) or from IQ-Products (Groningen, the Netherlands).
Goat-anti-mouse-F (ab¢)2-fragments (GaM-F(ab¢)2) and goat-anti-
human-F(ab¢)2-fragments (GaH-F(ab¢)2) used for cross-linking of
respectively mouse-and human anti-CD20-antibodies were obtained
from Jackson Laboratories (West Grove, PA, USA) as well as 
anti-human lgM-antibody. The anti-CD3-antibody B-B11 was
obtained from lQ-Products. 
Hybrid hybridoma fusion, subcloning of quadroma
cells and characterization of the antibodies produced
by the sub-clones 
A quadroma cell line was derived after fusion of the hybridoma
cell lines B-ly1 (anti-CD20, lgG1; Poppema and Visser, 1987) and
CLB-T3/4.2B (anti-CD3e, lgG2b; van Lier et al, 1987a,b). Fusion
was performed by standard hybrid hybridoma fusion techniques as
described previously (Kroesen et al, 1993). Briefly, a HGPRT-
negative anti-CD3e hybridoma cell line was selected by cultur-
ing it in 8-azaguanine containing medium. This hybridoma cell
line, unable to grow in hypoxantine, aminopterine- and thymidine-
(HAT) containing medium, was made neomycin resistant by retro-
viral transfection. This HAT sensitive, neomycin-resistant cell line
was then fused with the HAT-resistant, neomycin-sensitive
hybridoma cell line B-ly1. Standard polyethyleneglycol (PEG)
fusion procedures were used. Quadroma cells were subcloned in
96-well plates and clones producing both IgG1- and IgG2b-chains
were identified by detection of fluorescence after labelling the
quadroma cells with FITC- or TRITC-labelled anti-IgG1- or anti-
IgG2b-antibodies. One subclone was selected. In order to validate
CD20- and CD3e-binding capacity of the antibodies produced by
this clone, culture supernatant was harvested and applied to CD20-
positive JY cells or CD3e-positive CTLL/CD3e cells. 
Partial purification of BIS20x3 
Twice weekly antibody-producing cells were seeded in PFHM-II
medium. Supernatant was harvested when the number of dead
cells exceeded 30%. Approximately 500 ml supernatant was
collected and concentrated 103 using the ProVario-3FP concen-
trator (Filtron Technology BV, Terheyden, the Netherlands).
Antibody purification was performed by FPLC (Pharmacia,
Uppsala, Sweden). Concentrated supernatant was diluted two-fold
in 0.1 M K-phosphate buffer pH 8.2 (equilibration buffer) and
loaded onto a protein-A column. Antibodies were eluted using a
0.1 M Na-citrate buffer pH-gradient, decreasing from pH 6 to pH
2. Supernatants of the parental hybridomas were subjected to the
same procedure in order to determine at which pH the parental
antibodies elute from the column. During elution protein peaks
were detected spectrophotometrically (OD280) and 0.5 ml frac-
tions were collected. In each fraction the pH was measured and
neutralized by adding increasing volumes of a 1 M K-phosphate-
solution (pH 9.4). Each fraction was analysed for the presence of
IgG1- and/or IgG2b-isotype antibody chains by FACS analysis
(Epics Elite, Coulter, Hialeah, USA) using the antibodies
described above. The presence of the various antibody species was
confirmed by SDS/PAGE gel electrophoresis and subsequent
Western blotting. 
Detection of DNA fragmentation after cross-linking of
anti-CD20-antibodies on CD20-positive cells 
To induce apoptosis Ramos cells were harvested and incubated for
30 min with the different anti-CD20-antibody concentrations (see
Results) at 37˚C. The cells were washed to remove unbound anti-
body and plated at a concentration of 0.5–1 x 106 per well (6 well
plates, 2.5 ml per well). Cross-linking was achieved by adding
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was performed to determine the percentage (%) apoptotic cells in
the population. This assay is based on detection of a hypo-ploid
DNA peak by FACS analysis (Nicoletti et al, 1991). After 16 h
apoptosis induction the cells were washed in PBS containing 1%
BSA and resuspended in 0.2% Na-citrate/0.2% Triton X-100/
0.2 mg ml–1 RNase-A. DNA was stained by adding 100 mg ml–1 PI.
PI fluorescence was measured by FACS. 
Detection of T-cell activation after CD3e-cross-linking 
A TCR-beta chain negative Jurkat cell line harbouring an NFAT-
luciferase reporter gene named Jurkat-AM, was retrovirally trans-
duced with genes encoding the alpha and beta TCR chains from an
HLA-A2-restricted anti-MAGE-3 T-cell clone (van der Bruggen 
et al, 1994). The resulting subline is called Jurkat-AM/T. Transduction
restored CD3e-expression on the surface of Jurkat-AM/T as was
determined by FACS (not shown). After binding of anti-CD3e-anti-
bodies to Jurkat-AM/T, the NFAT-promoter becomes activated
which results in luciferase expression. Approximately 1.5 x 106 cells
per well (24 well plates) were activated during the period chosen.
When necessary 0.5 x 106 Ramos cells were added. The cells were
harvested and washed once. Pellets were frozen at –20˚C for at least
15 min to facilitate lysis which was performed in lysis buffer
supplied by the manufacturer of the Luciferase Assay System
(Promega, Leiden, The Netherlands). Luciferase activity was
detected using the same kit. Luminescence was detected on the
Anthos Lucy Microplate Luminometer and Photometer (Labtech
International, Ringmer, UK). 
Cytotoxicity assays 
We have used the calcein-release assay (Lichtenfels et al, 1994) as
an alternative for the 51Cr-release assay to demonstrate that
BIS20x3 re-targets T-cells to CD20-positive cells. PBLs were
isolated from heparin-blood using lymfoprep according to proto-
cols described by the manufacturer. T-cells were activated and
expanded by incubation for 3 days in RPMI 1640 medium
containing 15% normal human poolserum and 5% WT-32 (anti-
CD3e-hybridoma) supernatant (Tax et al, 1983), followed by 2
days culturing in RPMI 1640 medium containing 15% normal
human poolserum and 100 IU ml–1 IL-2. JY-cells were used as the
CD20-positive target cells. JY cells were isolated, washed and
resuspended in X-VIVO-medium at a concentration of 2 x 106
cells ml–1. Calcein-AM was added to the cells in a concentration of
8 mM for 40 min, after which extracellular calcein-AM was
removed by washing. Calcein-AM is the acetoxy-methylester of
calcein which diffuses passively across cell membranes. In the
cytosol calcein-AM is converted into the fluorochrome calcein by
intracellular esterases. Calcein is retained in cells with intact
membranes due to its polar nature. We applied 2 x 104 labelled JY
target cells per well to 96-well plates, and varied the number of 
T-cells (also washed and resuspended in X-VIVO-medium) to obtain
varying effector-target cell ratios. After 2 h incubation in the
absence or presence of different antibodies, the cells in the plates
were pelleted and the supernatant was transferred into a new 
96-well plate. Calcein fluorescence in the supernatant was determined
on the Bio-Tek FL500 fluorescence plate reader (BioTek®
Instruments Inc, Burlington, USA; excitation at 485 nm, emission
at 530 nm). The % cytotoxicity was calculated using the equation:
(Fsample – Fspontaneous release) / (Ftotal lysis – Fspontaneous release) x 100% = %
cytotoxicity. Total lysis values were obtained by addition of 0.5%
Triton X-100 to labelled JY cells. The 51Cr-release assay was
performed as described previously (Kroesen et al, 1995). 
RESULTS 
Hybrid hybridoma fusion 
The quadroma cell line producing BIS20x3 was made by fusion of
B-ly1 and CLB-T3/4.2B. The quadroma was screened for expres-
sion of both parental antibody chains and cultured after sub-
cloning twice. A clone displaying more than 95% double positive
cells was selected as the ‘producer’ cell line. Additionally, culture
supernatant was applied to CD20- or CD3e-positive cell lines (JY
or CTLL/CD3e respectively). The co-presence of antibody-chain
subclasses which do not bind by themselves on the target cells
(anti-CD20-chains (of lgG1-subclass) on CTLL/CD3e cells or
anti-CD3e-chains (of lgG2b-subclass) on JY-cells) suggested that
the bi-specific antibody was formed and confirmed the antigen-
binding capacity of both chains (results not shown). 
Isolation and partial purification of the bispecific
antibody (BIS20x3) 
Culture supernatants from B-ly1-(anti-CD20), CLB-T3/4.2B- (anti-
CD3e) or the quadroma culture were isolated and concentrated.
First, samples of the concentrated parental hybridoma supernatants
were mixed and loaded onto a protein-A FPLC column to elucidate
the pH-elution profile of both parental antibodies. Using FACS- and
Western blot analysis it was shown that the parental anti-CD20-anti-
body B-ly1 leaves the column between pH 5.5 and pH 4 and that the
anti-CD3e-antibody elutes between pH3 and 2 (peak at pH 2.5). In
Figure 1 the elution profiles are depicted. The results suggest that
the parental antibodies can be separated from each other. After
loading quadroma supernatant and subsequent antibody elution
using the same pH gradient, it was demonstrated that the bi-specific
antibody leaves the column at a pH value lower than pH 3.8
indicating that the bi-specific antibody, which was called BIS20x3,
could be isolated without ‘contaminating’ B-ly1. However, the
BIS20x3 peak overlaps partially with the anti-CD3e-peak.
Therefore it was decided to use only the fractions isolated from the
first half of the BIS20x3-peak for the experiments described below
(more than 90% pure regarding BIS20x3-content). To check the
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Figure 1 Schematic representation of the pH elution profiles of both
parental antibodies (B-ly1 and CLB-T3/4.2b) and the bispecific antibody
(BIS20x3). The double arrow indicates the fractions used for the experiments
described in this paper functionality of the antigen-binding capacity of both arms of the
bispecific antibody, assays were subsequently performed which
detect the intracellular signals which are relayed after binding of
antibodies to CD20 on B-cells or CD3e on T-cells, respectively. 
Detection of DNA hypo-ploidy after cross-linking of
anti-CD20-antibodies on Ramos-cells 
It was reported that binding of anti-CD20-antibodies to CD20 and
subsequent cross-linking of these antibodies leads to apoptosis
induction in Ramos cells (Shan et al, 1998). From Figure 2A and
2B it can be concluded that B-ly1 cross-linking leads to similar
DNA-fragmentation percentages as when Rituximab is cross-
linked. A dosage of only 0.1–0.5 mg ml–1 B-ly1 or Rituximab is
enough to detect apoptotic cells after cross-linking during 16 h.
Also shown is that addition of anti-CD20 antibody alone or cross-
linking antibody alone does not affect the Ramos cells. As a
control anti-IgM-antibody was applied, resulting in high percent-
ages of DNA fragmentation. Also cross-linking of BIS20x3 leads
to DNA fragmentation in Ramos cells (Figure 2C), becoming
evident at a BIS20x3 concentration of 0.5 mg ml–1. The levels of
DNA fragmentation appear to be higher than achieved in Figure
2A, B, however it has to be remarked that the untreated control
shows already a relatively high apoptotic fraction in this experi-
ment. The results presented here demonstrate that the anti-CD20
chain of BIS20x3 is functionally active in inducing apoptosis upon
cross-linking. 
T-cell signalling induced by binding of BIS20x3 to
Jurkat-AM/T cells 
To demonstrate the functional capacity of the aCD3-chain of
CD20x3 to activate T-cells, a CD3e-signalling assay was used
which was described in the Materials and methods section. Figure
3A shows results obtained after binding of BIS20x3 to CD3e
expressed on the surface of Jurkat-AM/T cells, and subsequent
cross-linking of BIS20x3 by goat-anti-mouse-F(ab¢)2-fragments.
Cross-linking of increasing amounts of BIS20x3 results in
increasing levels of T-cell stimulation. As a positive control T-cells
were stimulated with WT-32 culture supernatant and as a negative
control no antibody was added. Because we also expected indirect
CD3e-cross-linking to occur (and therefore T-cell activation) when
Ramos cells were added to BIS20x3-coated Jurkat-AM/T cells, we
performed the experiment summarized in Figure 3B. In this graph
it is clearly shown that the T-cells are much more efficiently stimu-
lated when BIS20x3 is cross-linked via Ramos cells than when the
bi-specific antibody is cross-linked with goat-anti-mouse-F(ab¢)2-
fragments (Figure 3A), what may be caused by a co-stimulatory
capacity of the Ramos cells. The results presented in Figure 3
demonstrate the functional binding of BIS20x3 to CD3e. 
BIS20x3 re-targets PBL derived T-cells to CD20-positive
JY cells 
In Figure 4 representative results obtained with the calcein release
assay are presented. In Figure 4A it is shown that when using the
JY cell line, spontaneous release values were observed of approxi-
mately 25%. Neither the medium taken from unlabelled JY cell
cultures nor medium from unlabelled T-cell cultures displayed
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Figure 2 Apoptosis induction in Ramos cells after cross-linking of anti-
CD20 antibodies on the cell surface. In the experiment described in Figure
2A apoptosis was induced by cross-linking of B-ly1 which is the parental
antibody used for derivation of BIS20x3. In Figure 2B results obtained after
cross-linking of Rituximab are described. Figure 3C depicts results obtained
after cross-linking of BIS20x3. Abbreviations used: no Abs = no antibodies,
Bly = B-ly1, GaM = goat-anti-mouse-F(ab¢)2-fragments, IgM = anti-IgM-
antibody, Rit = Rituximab, GaH = goat-anti-human-F(ab¢)2-fragments,
Bis = BIS20x3. The numbers describe the amount of each antibody
(or antibody-fragment) applied, in mg ml–1. The data presented in this graph
are representative for 3 or more experimentsbackground fluorescence. Addition of 1 mg ml–1 B-ly1, CLB-
T3/4.2B or a combination of both parental antibodies to wells
containing T- and B-cells at an E/T-ratio of 20 had no effect. In
Figure 4B a representative CTL-assay is described. It is shown that
BIS20x3 re-targets PBL-derived, pre-activated T-cells to JY cells.
With increasing effector/target cell ratios increased cytotoxicity
%s were observed. These results could be reproduced readily indi-
cating the good reproducibility of this non-radioactive cytotoxicity
assay. Additionally, the results obtained by using the calcein
release assay were essentially similar to results obtained by 51Cr-
release (not shown). In none of the performed assays Rituximab
was able to cause B-cell lysis in the calcein-release assay as it was
performed here (essentially the results were similar to those
obtained for B-ly1 described in Figure 4A). Finally, Figure 4C
shows that the retargeting of T-cells to CD20 positive cells is
BIS20x3-concentration-dependent and that cytotoxicity can be
detected at BIS20x3 concentrations which are considerably lower
(factor 50) than the anti-CD20-antibody concentrations needed to
detect DNA fragmentation (Figure 2). 
DISCUSSION 
The anti-CD20-antibody Rituximab is concerning its ability to
induce tumour response rates the most effective anti-cancer antibody 
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Figure 3 Luciferase activity measured in extracts of Jurkat-AM/T cells after
different treatments. In Figure 3A it is shown that cross-linking of increasing
amounts of BIS20x3 (BIS) using goat-anti-mouse-F(ab¢)2-fragments (GaM)
leads to increasing T-cell activation. As a negative control no antibodies (no
Abs) were added and as a positive control 100 ml WT-32 supernatant (WT32)
was applied. In Figure 3B the remarkable results obtained after indirect
cross-linking via Ramos cells are presented. Cross-linking of varying
amounts (the numbers represent mg ml–1) of BIS20x3 on the surface of
Jurkat-AM/T-cells via Ramos cells, leads to a dramatic increase in T-cell
activation when compared with the results obtained after cross-linking using
goat-anti-mouse-F(ab¢)2-fragments. At higher levels of BIS20x3 the amount
of bispecific antibody saturates the available binding sites on both T- and B-
cells which prevents cross-linking and results in a decrease in T-cell
activation 
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Figure 4 In Figure 4A the calcein-release assay-controls are presented.
The maximal release value (obtained from Triton-treated cells) was set to
100% and the following bars show the %-release related to this value. Shown
are respectively: MR = maximal release, SR = spontaneous release, 
JY- = background fluorescence of medium in which unlabelled JY cells were
present, TC = background fluorescence of medium in which unlabelled 
T-cells were present, B-ly1 = effect of 0.5 mg ml–1 parental antibody B-ly1 on
labelled JY cells, CLB = effect of 0.5 mg ml–1 of other parental antibody 
CLB-T3/4.2B (0.5 mg ml–1), and B-ly1 + CLB = addition of 0.5 mg ml–1 B-ly1 +
0.5 mg ml–1 CLB-T3/4.2B. The last 3 bars represent results obtained after
adding the described antibodies to T- and B-cells at an E/T ratio of 20. Figure
4B shows representative results of the calcein-release assay. Cytotoxicity %s
were calculated by implementing the formula described in the materials and
methods section. BIS20x3 (0.5 mg ml–1) was used to retarget PBL-derived 
T-cells to CD20-positive JY-cells at different E/T ratios. The results of Figure
4A and 4B were obtained in the same experiment. Figure 4C shows that the
cytotoxicity is BIS20x3 concentration dependent (E/T-ratio of 20; 5, 10, 50
and 100 ng BIS20x3  ml–1). The data presented in this figure could be
reproduced in similar experiments in the clinic at present. Its success is most probably due to a diversity
of effects which are induced after binding to CD20. First, it has been
shown that Rituximab can kill via complement mediated lysis. Very
recently the C1q binding site on Rituximab has been identified
(Idusogie et al, 2000). The second mechanism by which Rituximab is
thought to elicit target cell death is via antibody-dependent cellular
cytotoxicity. Although both mechanisms are potent cell death activ-
ating routes it is thought that the efficacy of Rituximab is at least
partially due to additional mechanisms which are directly triggered
by CD20 upon binding of the antibody. The function of CD20 as a
signalling molecule has been investigated by several groups. It was
demonstrated that upon binding of anti-CD20 antibodies 95% of all
CD20 molecules present on the cell move to lipid rafts in the cell
membrane which are known to be important in cellular signalling
(Deans et al, 1998). It is thought that CD20 signals indirectly via
tyrosine kinases which are known to be present in these rafts and
which were shown to interact with CD20 (Deans et al, 1995) or
directly by functioning as a Ca2+-channel (Bubien et al, 1993; Tedder
and Engel, 1994). Recently it was demonstrated that cross-linking of
anti-CD20 antibodies on the surface of B-cells using F(ab¢)2-
fragments or Fc-receptor positive cells induces apoptosis in B-cells
(Shan et al, 1998). The same group confirmed that protein tyrosine
kinases, increased intracellular Ca2+-concentrations, and caspases are
involved (Shan et al, 2000). In the latter paper it was also shown that
CD95 (Fas) becomes up-regulated after cross-linking of anti-CD20-
antibodies on B-cells, but that the Fas-FasL route is not important in
the in vitro setting. However, this may have important consequences
for the in vivo setting. Increased Fas expression could make
Rituximab treated B-cells more sensitive for FasL produced by other
cells, especially by T-cells (Shresta et al, 1998). This is an important
notion, especially in the context of T-cell re-targeting e.g. using the
bi-specific antibody described in this paper. 
Although several effector mechanisms seem to be triggered by
Rituximab, 50% of NHL-patients do not respond. Recently, also
patients with CD20-positive post-transplantation lymphoprolifera-
tive disorder (PTLD) were treated with Rituximab and also in this
group 30% of the patients did not respond (Milpied et al, 2000).
Various escape mechanisms which cause this non-responsiveness
can be envisaged (e.g. a relative tumour cell-resistance to apop-
tosis induction). We hypothesize that the efficacy of treatment will
increase when the delivered apoptotic signal can be strengthened
and we think that this can be achieved by retargeting T-cells
(professional killers) to CD20-positive cells using the bi-specific
antibody BIS20x3 described in this paper. 
To evaluate BIS20x3 it was investigated whether the purified
product was able to induce the signals which are known to be
relayed by each of its parental antibodies. Using the Burkitt
lymphoma cell line Ramos as a model system in analogy to experi-
ments performed by Shan et al (1998) we were able to demonstrate
that apoptosis was induced after cross-linking of the parental anti-
CD20 antibody B-ly1, Rituximab or BIS20x3. DNA fragmenta-
tion was detectable after overnight incubation using antibody
concentrations of 0.1–0.5 mg ml–1, which is considerably lower
than the concentrations used by Shan et al (10 mg ml–1). In the
experiment depicted in Figure 2C it may seem that BIS20x3 cross-
linking results in more efficient apoptosis induction (35% at a
concentration of 5 mg ml–1) than after cross-linking of B-ly1 or
Rituximab (approximately 21% at a concentration of 5 mg ml–1).
However, it has to be pointed out that background apoptosis was
rather high in this experiment compared to the experiments
summarized in Figure 2A and 2B, which obviously influences the
results. BIS20x3 induces simi percentages of apoptotic cells as
B-ly1 or Rituximab, although BIS20x3 contains only 1 CD20-
binding site while B-ly1 Rituximab contain two. It is likely that at
the used B-ly1 and Rituximab concentrations these 2 antibodies
bind monovalently. If Rituximab is cross-linked in vivo by Fc-
receptor positive cells as was suggested by Shan, and if this
phenomenon contributes significantly to Rituximab efficacy, our
results imply that T-cell retargeting anti-CD20 bi-specific anti-
bodies may be at least as effective in apoptosis induction when
bound to B-cells as Rituximab. 
The other chain of BIS20x3 targets CD3e on T-cells. Binding of
antibodies to CD3e activates T-cells. We were able to demonstrate
T-cell activation upon cross-linking of BIS20x3 on its surface
using goat-anti-mouse F(ab¢)2-fragments (Figure 3A). To obtain
these results relatively high BIS20x3-concentrations have to be
used (compare the amounts used in Figure 3A with the amounts
used in to obtain the results presented in Figure 3B). 
T-cell activation could be enhanced dramatically by using Ramos
cells as indirect cross-linkers instead of the F(ab¢)2-fragments
(Figure 3B). The enhanced T-cell activation found in this situation
is most probably caused by co-stimulatory signals given by the
Ramos cells. These results suggest that B-cell malignancies may
be ideal targets for T-cell retargeting bi-specific antibody-based
therapies because the retargeted T-cells will be activated most
effectively (Chaperot et al, 2000). This finding also suggests that
no additional co-stimuli need to be given, which was suggested
when T-cells are retargeted to other types of malignant target cells
(discussed in Kroesen et al, 1998). The results in Figure 3B also
suggest that for optimal effects the bi-specific antibody concentra-
tion needs to be titrated, which may become an issue when dose-
escalating clinical studies are planned. If the concentration of
bi-specific antibody gets too high the binding sites on T- and B-cells
may become saturated without cross-linking the cells to each other.
Although it is theoretically possible that our quadroma produces
up to 10 different immunoglobulin molecules due to shuffling of
the heavy and light chains (Kroesen et al, 1998), our purified
product is very efficient in retargeting T-cells to B-cells (Figure 4).
This was expected because in general the percentage of unwanted
heavy/light chain combinations is low because each heavy chain
has the highest affinity for its own light chain. Moreover, the most
important and most abundant ‘contaminants’, the parental mono-
specific species, were certainly not isolated (see Figure 1). The
experiments above and the high retargeting efficiency therefore
suggest that the bispecific antibody is present in abundant
amounts. The high cytotoxicity observed may be due to optimal T-
cell activation caused by co-stimulatory signals delivered by the
B-cells and/or by the increased sensitivity of the B-cells for FasL
after binding of anti-CD20 antibodies. Although we did not
address this question in this study it will be interesting to invest-
igate if in the bi-specific setting, the apoptosis-inducing signal
induced upon anti-CD20-crosslinking plays an important role or
whether the T-cell-mediated signal is far more efficient. Another
important question is if BIS20x3 is more efficient in treating
lymphomas than CD19xCD3 bispecific antibodies. Several
CD19xCD3 bispecific antibodies have been described recently
(Daniel et al, 1998; Cochlovius et al, 2000; Löffler et al, 2000) in
several antibody-formats (quadroma-derived, bi-specific single-
chain and diabody respectively). The findings that CD20 seems to
be higher expressed on B-cells compared to CD19 and that CD20
is not internalized after antibody binding in contrast to CD19-anti-
body complexes are often used as arguments for the use of CD20
1120 S Withoff et al
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antibodies with BIS20x3 would be very informative in this matter.
The application of T-cell retargeting anti-CD20 antibodies in
therapies for B-cell malignancies may be an improvement upon
Rituximab-based therapies. Our finding that T-cells are very effi-
ciently activated in a setting in which B-cells are present is very
promising in this respect. This characteristic is probably caused by
the fact that unlike most other cancer cells, malignant B-cells may
be capable to function as antigen-presenting cells (Chaperot et al,
2000). Also the recent finding that after cross-linking of anti-
CD20-antibodies on B-cells Fas is up-regulated in these cells
(Shan et al, 2000) could have major implications for T-cell retar-
geting-based lymphoma therapies, because this will make the 
B-cells even more sensitive for FasL on activated T-cells. 
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